{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-25-000008","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.321399+00:00","generated_at":"2026-05-26T04:57:24.324516+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Senti Bio appoints Jay Cross as CFO and Faraz Siddiqui as SVP Technical Operations","bullets":["Jay Cross appointed CFO effective March 3, 2025; base salary $465k, annual target bonus 40%, sign-on bonus $50k repayable if leaving before 14 months.","Stock option for 174,200 shares (or 44,000 if stockholder proposal fails) under 2022 Inducement Plan; four-year vesting.","Faraz Siddiqui joined as SVP Technical Operations in Jan 2025; oversees manufacturing, supply chain; previously at IGM Biosciences, Instil Bio, Kite Pharma, Genentech.","CEO Timothy Lu served as interim principal financial officer from Jan 31 until 10-K filing when Cross assumes role."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-25-000008","json":"https://secwatch.observer/filing/0001854270-25-000008.json","markdown":"https://secwatch.observer/filing/0001854270-25-000008.md","text":"https://secwatch.observer/filing/0001854270-25-000008.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000008/0001854270-25-000008-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000008/snti-20250223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T04:57:24.324516+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd48a89660","claim":"Jay Cross was appointed as Chief Financial Officer at Senti Biosciences, Inc..","evidence_excerpt":"Jay Cross was appointed as the Company’s Chief Financial Officer, effective as of March 3, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427025000008/0001854270-25-000008-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}